En pacientes adultos con anemia que reciben un estimulador de la eritropoyesis, no se recomienda la corrección rutinaria a niveles de Hemoglobina superior a 12 g/dl(ajustar dosis para nivel Hb deseado entre 10 y 12 g/dl).

National Institute for Health and Care Excellence (NICE) 2011. Clinical Guideline Nº 114 (CG 114). Anaemia management in people with chronic Kidney disease

Kidney Disease: Improving Global Outcomes (KDIGO). Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International Suppl 2012;2:279-335.

Locatelli F, Bárány P, Covic A, Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W, on behalf of the ERA-EDTA ERBP Advisory Board. Kidney Disease:Improving Global Outcomes Guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28:1346-1359.

Palmer SC et al. Meta-analysis: erythropoiesis stimulatin agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23-33

Vinhas J, Barreto C, Assuncao J, Parreira L, Vaz A. Treatment of anaemia with erytropoiesis stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: a meta-analysis. Nephron Clin Pract 2012;121(3-4):c95-101

. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis stimulating agents and adverse outcomes in CKD: A meta-regression analysis. Am J Kidney Dis 2013;61(1):44-56.